Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of hypotensive effect and prevention to progression of diabetic nephrolopathy with Olmesartan and Ca channel blocker in patient of type 2 diabetes

Next Previous
Trial Profile

Comparison of hypotensive effect and prevention to progression of diabetic nephrolopathy with Olmesartan and Ca channel blocker in patient of type 2 diabetes

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Amlodipine; Azelnidipine
  • Indications Diabetic nephropathies; Hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms SORT

Most Recent Events

  • 22 Apr 2019 Status changed from recruiting to discontinued.
  • 08 Nov 2012 Lead trial centre deleted as reported by University Hospital Medical Information Network - Japan.
  • 29 Aug 2012 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top